RxDoctor Payments Data

Kathleen Koehler, MD

Internal Medicine · Vineyard Haven, MANPI 1013967140

Payments from drug & device makers

$914in general payments, 2019–2025

Across 19 payments — averaging $48.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$307
  • E.r. Squibb & Sons, L.L.C.$252
  • Lilly USA, LLC$120
  • Novo Nordisk$94
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$41
  • Astellas Pharma US Inc$40
  • plus $60 from 3 others

What the payments were for

  • Food & beverage$914100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$914 in reported general payments places this provider in the 80th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$201,293
Medicare patients
462
Services billed
3,301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban61$54,573
XifaxanRifaximin11$36,128
XareltoRivaroxaban16$20,299
JardianceEmpagliflozin14$16,266
OzempicSemaglutide13$11,461
Zolpidem Tartrate67$2,830
Atorvastatin Calcium251$2,471
Rosuvastatin Calcium42$2,118
Estradiol18$2,087
Metoprolol Succinate78$1,861
Losartan Potassium164$1,640
PaxlovidNirmatrelvir/Ritonavir13$1,429
Levothyroxine Sodium136$1,383
Omeprazole86$1,238
SynthroidLevothyroxine Sodium19$1,138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$16$56,00274 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$41$36,12811 claims
Novo NordiskOzempic$94$11,46113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Vineyard Haven

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →